Tech workers in Silicon Valley are increasingly experimenting with gray-market peptide drugs from China, legal for personal use, for improving focus and more
Jayden Clark first heard about Chinese peptides at his Fourth of July party this past year. — In the backyard of a San Francisco …
New York TimesJasmine Sun
Context & Ripple Effects
Silicon Valley coverage has already documented drug use moving into corporate culture, while a recent report described startups offering nicotine pouches as a focus-oriented perk. The peptide experimentation extends that performance-enhancement logic to products workers source themselves rather than through employers.
The China link also arrives amid reporting on Chinese biotech’s growing relevance to Western drug companies, though this story concerns gray-market personal use rather than formal pharma partnerships.
First-order effects
Tech workers experimenting with Chinese peptides gain a personal-use route to pursue focus and other performance effects outside conventional workplace benefit programs.
Employers and managers face a harder distinction between private conduct and workplace performance or impairment when the substances are framed as productivity tools.
Demand for informal sourcing can widen the gap between employer wellness policies and the substances workers actually use, putting greater weight on disclosure, safety, and conduct rules rather than benefit design.
Third-order effects
If such experimentation broadens, performance enhancement may become a more explicit—yet largely employee-managed—part of tech workplace culture, with organizational policies lagging behind new supply channels.
The pattern could intensify debate over whether productivity pressures are being addressed through work design or through individual chemical optimization; the current coverage does not establish how widespread peptide use is.
The trend: Silicon Valley’s pursuit of individual productivity enhancement is shifting from social drug culture toward workplace-adjacent, self-sourced substances marketed around focus and performance.
The discourse around Chinese peptides cleanly divides two classes of elites: Tech elites who say “you can just do things” and biopharma elites who say “trust the experts” I believe the most important dynamic in biotech in 2026 is the decisive shift in favor of the tech side
@jasminewsun i come from the steroid world and i think everyone collectively regrets not gatekeeping this world better from these SV freaks, facebook moms group purchasers, or tiktok teens buying them on sketchy clearweb sites. regular people should have never known about these t…
@carygee1 not all but most, China generally has better mass manufacturing ecosystems + probably looser quality standards (eg non cGMP approved factories)
@jasminewsun Nailed it on Odd Lots. You were very clear and knew the topic... one of the better guests. The whole thing sounds insane to me. I wouldn't be surprised if there are some hard lessons learned about how biological science works and eventual litigation
given the amount of organizational effort we put into this (+ the fact that it was literally @Bonecondor's birthday party) seems insane that we were not mentioned in this article! but there's a cute picture of my arm 🫠 next party will be even more epic https://www.nytimes.com/...
very fun reporting this because the peptide story is about biohacking, supply chains, pharma regs, and a million other things that did not fit in the 2k word limit thank you to @creatine_cycle, @typesfaster, @gptbrooke, @EricTopol, @AnelyaGrant, @paulabramsonmd, @akesselheim, [im…
To nitpick a little, I believe what I said was that I don't like the term transhumanist but that most people would probably consider me one.. Overall though, the article was fun! I'm a little crestfallen they didn't wind up using any of the photos they took of me, had a lot of
I'm quoted in today's NYT on the “Chinese peptides” trend. My take: “The entrepreneurial parallel isn't funding a scrappy startup. It's wiring money to an unregistered offshore entity based on a pitch deck.” https://buff.ly/n5nEobl [image]
@gptbrooke bummer about the photos, didn't get to choose those or captions! the transcript I have on transhumanism is “Under most definitions, I probably qualify as one” and then the microchip anecdote — you didn't mention not liking the term, so that was my interp, but noted for…
Injecting mysterious Chinese drugs to code 12% faster: A-Ok, funky trend Injecting Estrogen to Trans your Gender: Sinister, need 500 op-Eds about how it's unprecedented
@gavinpurcell I think Odd Lots was also me haha The GLPs (semaglutide, tirzepatide, retatrutide) are the most tested; the other peptides like BPC have very little human trial evidence / the risk profile is much higher. Gray-market sourcing is also another big risk vector, and the…
This article in the Times does a great job laying out the perspectives, richly sampling quotes from both biopharma and tech culture, pro-peptide and anti-peptide https://www.nytimes.com/...